Shanghai Pharmaceuticals Holding Co., Ltd

SHSE:601607 Stock Report

Market Cap: CN¥71.6b

Shanghai Pharmaceuticals Holding Management

Management criteria checks 2/4

Shanghai Pharmaceuticals Holding's CEO is Bo Shen, appointed in Mar 2010, has a tenure of 14.75 years. total yearly compensation is CN¥5.80M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth CN¥1.39M. The average tenure of the management team and the board of directors is 2.3 years and 1.5 years respectively.

Key information

Bo Shen

Chief executive officer

CN¥5.8m

Total compensation

CEO salary percentage21.5%
CEO tenure14.8yrs
CEO ownership0.002%
Management average tenure2.3yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

Is Shanghai Pharmaceuticals Holding (SHSE:601607) A Risky Investment?

Dec 19
Is Shanghai Pharmaceuticals Holding (SHSE:601607) A Risky Investment?

Shanghai Pharmaceuticals Holding (SHSE:601607) Has More To Do To Multiply In Value Going Forward

Dec 03
Shanghai Pharmaceuticals Holding (SHSE:601607) Has More To Do To Multiply In Value Going Forward

Not Many Are Piling Into Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Just Yet

Sep 30
Not Many Are Piling Into Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Just Yet

Shanghai Pharmaceuticals Holding (SHSE:601607) Has Some Way To Go To Become A Multi-Bagger

Aug 09
Shanghai Pharmaceuticals Holding (SHSE:601607) Has Some Way To Go To Become A Multi-Bagger

Shanghai Pharmaceuticals Holding's (SHSE:601607) Dividend Is Being Reduced To CN¥0.41

Jul 18
Shanghai Pharmaceuticals Holding's (SHSE:601607) Dividend Is Being Reduced To CN¥0.41

Shanghai Pharmaceuticals Holding (SHSE:601607) Has A Somewhat Strained Balance Sheet

Jun 25
Shanghai Pharmaceuticals Holding (SHSE:601607) Has A Somewhat Strained Balance Sheet

Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Earnings Are Not Doing Enough For Some Investors

May 21
Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Earnings Are Not Doing Enough For Some Investors

Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Apr 01
Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Returns At Shanghai Pharmaceuticals Holding (SHSE:601607) Appear To Be Weighed Down

Mar 16
Returns At Shanghai Pharmaceuticals Holding (SHSE:601607) Appear To Be Weighed Down

We Think Shanghai Pharmaceuticals Holding (SHSE:601607) Can Stay On Top Of Its Debt

Feb 29
We Think Shanghai Pharmaceuticals Holding (SHSE:601607) Can Stay On Top Of Its Debt

CEO Compensation Analysis

How has Bo Shen's remuneration changed compared to Shanghai Pharmaceuticals Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥4b

Jun 30 2024n/an/a

CN¥4b

Mar 31 2024n/an/a

CN¥4b

Dec 31 2023CN¥6mCN¥1m

CN¥4b

Sep 30 2023n/an/a

CN¥5b

Jun 30 2023n/an/a

CN¥5b

Mar 31 2023n/an/a

CN¥6b

Dec 31 2022CN¥6mCN¥1m

CN¥6b

Sep 30 2022n/an/a

CN¥5b

Jun 30 2022n/an/a

CN¥5b

Mar 31 2022n/an/a

CN¥4b

Dec 31 2021CN¥6mCN¥1m

CN¥5b

Sep 30 2021n/an/a

CN¥5b

Jun 30 2021n/an/a

CN¥6b

Mar 31 2021n/an/a

CN¥6b

Dec 31 2020CN¥5mCN¥1m

CN¥4b

Sep 30 2020n/an/a

CN¥4b

Jun 30 2020n/an/a

CN¥4b

Mar 31 2020n/an/a

CN¥4b

Dec 31 2019CN¥6mCN¥1m

CN¥4b

Sep 30 2019n/an/a

CN¥4b

Jun 30 2019n/an/a

CN¥4b

Mar 31 2019n/an/a

CN¥4b

Dec 31 2018CN¥3mCN¥800k

CN¥4b

Sep 30 2018n/an/a

CN¥4b

Jun 30 2018n/an/a

CN¥4b

Mar 31 2018n/an/a

CN¥4b

Dec 31 2017CN¥2mCN¥800k

CN¥4b

Compensation vs Market: Bo's total compensation ($USD794.63K) is above average for companies of similar size in the CN market ($USD368.88K).

Compensation vs Earnings: Bo's compensation has been consistent with company performance over the past year.

CEO

Bo Shen (51 yo)

14.8yrs

Tenure

CN¥5,800,000

Compensation

Mr. Bo Shen has been the Chief Financial Officer of Shanghai Pharmaceuticals Holding Co., Ltd. since March 2010 and serves as its Head of the Accounting Department. He serves as President of Shanghai Pharm...

Leadership Team

NamePositionTenureCompensationOwnership
Qiuhua Yang
Executive Chairmanless than a yearno datano data
Bo Shen
President14.8yrsCN¥5.80m0.0019%
CN¥ 1.4m
Yongzhong Li
VP & Executive Directorno dataCN¥6.19mno data
Ming Dong
Executive Director1.5yrsno datano data
Tao Zhong
VP, Board Secretary & Joint Company Secretary2.3yrsCN¥3.12mno data
Dongming Li
Vice President2.8yrsCN¥3.12mno data
Shuai Shao
Vice President2.3yrsCN¥2.08mno data
Shunjiang Yu
Chief Medical Officerno datano datano data
Pui Kiu Wong
Joint Company Secretaryless than a yearno datano data
Ying Ke
Director & General Manager of R&D Management Centerno datano datano data
Linqiong Dong
Securities Affairs Representativeno datano datano data

2.3yrs

Average Tenure

52yo

Average Age

Experienced Management: 601607's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Qiuhua Yang
Executive Chairmanless than a yearno datano data
Bo Shen
President11.5yrsCN¥5.80m0.0019%
CN¥ 1.4m
Yongzhong Li
VP & Executive Director11.5yrsCN¥6.19mno data
Ming Dong
Executive Director1.5yrsno datano data
Wenxue Zhang
Non-Executive Directorless than a yearno datano data
Manson Fok
Independent Non-Executive Director5.5yrsCN¥300.00kno data
Youli Xu
Chief Supervisor8.5yrsno datano data
Zhaoyang Gu
Independent Non-Executive Director5.5yrsCN¥300.00kno data
Weidong Yu
Employee Representative Supervisor1.5yrsno datano data
Jia Ma
Supervisor1.5yrsno datano data
Zhong Wang
Independent Non-Executive Director1.5yrsCN¥150.00kno data

1.5yrs

Average Tenure

53yo

Average Age

Experienced Board: 601607's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:47
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Pharmaceuticals Holding Co., Ltd is covered by 52 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xing Qiu LinAJ Securities Co., Ltd
Zhi Xue DiaoAvic Securities Co., Ltd
Derrick SunBNP Paribas Securities (Asia)